Vigil Neuroscience, Inc. (VIGL)
After hours:
| Previous Close | 4.3700 |
| Open | 4.2600 |
| Bid | 4.3000 x 400 |
| Ask | 4.3500 x 300 |
| Day's Range | 4.0200 - 4.4200 |
| 52 Week Range | 2.4700 - 11.1100 |
| Volume | |
| Avg. Volume | 166,253 |
| Market Cap | 162.74M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.1200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.75 |
GlobeNewswireVigil Neuroscience to Present in Upcoming June Investor Conferences
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced management’s participation at two upcoming investor conferences. Ivana Magovčević-Liebisch, Ph.D., J.D., President & Chief Executive Officer and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Jefferies Global Healthcare
ZacksAll You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
Vigil Neuroscience (VIGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14th at 11:30 a.m. E.T. To register for the live event, please click here. The webcast will also be available on the Company’s website on the “E
